RxDoctor Payments Data

Kevin Sierra, MD

Critical Care Medicine · Tampa, FLNPI 1659318913

Payments from drug & device makers

$7,036in general payments, 2019–2025

Across 298 payments — averaging $23.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • AstraZeneca$1K
  • Inari Medical, Inc.$549
  • Sanofi$385
  • Amgen$370
  • Regeneron Healthcare Solutions, Inc.$346
  • plus $3K from 43 others

What the payments were for

  • Food & beverage$7,019100%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,036 in reported general payments places this provider in the 85th percentile of 618 critical care medicine providers in Florida.

See all critical care medicine providers in Florida

Medicare billing

Part B allowed, 2024
$612,612
Medicare patients
1,037
Services billed
5,316

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Fasenra PenBenralizumab12$79,042
Trelegy ElliptaFluticasone/Umeclidin/Vilanter81$72,226
Breo ElliptaFluticasone/Vilanterol94$48,323
Spiriva RespimatTiotropium Bromide41$34,736
SymbicortBudesonide/Formoterol Fumarate42$15,020
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$14,021
Advair HfaFluticasone Propion/Salmeterol15$8,751
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$7,565
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$5,455
Wixela InhubFluticasone Propion/Salmeterol24$4,509
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$3,988
Albuterol Sulfate HfaAlbuterol Sulfate137$2,962
Theophylline ErTheophylline Anhydrous21$2,583
Montelukast Sodium59$496
Rosuvastatin Calcium27$314

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$1,092$126,004188 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$317$42,30153 claims
AstraZenecaSymbicort, Breztri Aerosphere$1,078$29,04160 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 618 critical care medicine providers in Florida.

Other critical care medicine in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →